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Abstract
Background: In real-time RT quantitative PCR (qPCR) the accuracy of normalized data is highly
dependent on the reliability of the reference genes (RGs). Failure to use an appropriate control
gene for normalization of qPCR data may result in biased gene expression profiles, as well as low
precision, so that only gross changes in expression level are declared statistically significant or
patterns of expression are erroneously characterized. Therefore, it is essential to determine
whether potential RGs are appropriate for specific experimental purposes. Aim of this study was
to identify and validate RGs for use in the differentiation of normal and tumor lung expression
profiles.
Methods: A meta-analysis of lung cancer transcription profiles generated with the GeneChip
technology was used to identify five putative RGs. Their consistency and that of seven commonly
used RGs was tested by using Taqman probes on 18 paired normal-tumor lung snap-frozen
specimens obtained from non-small-cell lung cancer (NSCLC) patients during primary curative
resection.
Results: The 12 RGs displayed showed a wide range of Ct values: except for rRNA18S (mean 9.8),
the mean values of all the commercial RGs and ESD ranged from 19 to 26, whereas those of the
microarray-selected RGs (BTF-3, YAP1, HIST1H2BC, RPL30) exceeded 26. RG expression stability
within sample populations and under the experimental conditions (tumour versus normal lung
specimens) was evaluated by: (1) descriptive statistic; (2) equivalence test; (3) GeNorm applet. All
these approaches indicated that the most stable RGs were POLR2A, rRNA18S, YAP1 and ESD.
Conclusion: These data suggest that POLR2A, rRNA18S, YAP1 and ESD are the most suitable
RGs for gene expression profile studies in NSCLC. Furthermore, they highlight the limitations of
commercial RGs and indicate that meta-data analysis of genome-wide transcription profiling studies
may identify new RGs.
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Background
Lung cancer remains the leading cause of cancer-related
death in Europe and North America and accounts for
nearly 30% of the total [1,2]. Despite advances in treat-
ment, the prognosis of non-small cell lung cancer
(NSCLC) is poor: only 5–15% of patients survive 5 years
after diagnosis, mainly in function of the initial stage of
the disease [3]. Real-time quantitative PCR (qPCR) is the
foremost method of choice for accurate determination of
transcripts amounts. It has recently been applied in lung
cancer studies to quantify the expression level of predic-
tive and/or prognostic target genes [4,5].
In gene expression studies, qPCR data need to be normal-
ized to remove nonspecific variability associated with dif-
ferences in RNA quantity and quality, usually by relative
quantification whereby the expression level of the target
gene is determined relatively to another gene transcript,
the so-called reference gene (RG), and the results are
expressed as a target to reference ratio [6]. The reliability
of normalized data is highly dependent on RG robustness.
An ideal RG should be constitutively expressed and char-
acterized by stable expression in different samples/experi-
mental conditions.
Genes considered to be valid RGs in semi-quantitative
techniques (eg. Nothern Blot) may be less reliable when
highly sensitive qPCR is used [7]. Identification of more
sensitive RGs and their validation within specific biologi-
cal conditions are thus critical issues in qPCR studies [8].
Microarray data can be used to identify potential RGs by
modeling the expression data to select those with the
most stable expression [9-11]. Most lung cancer qPCR
studies use commercial RGs, such as glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) [12], β-actin (ACTB)
[13], TATA-binding protein [14], β-microglobulin [15],
cytochrome oxidase II [16], 18S ribosomal RNA
(rRNA18S) [4]. Their reliability in this contex, however,
has not been demonstrated. Furthermore, it is increas-
ingly evident that in many experimental situations the use
of GAPDH or ACTB is inappropriate due to their high var-
iability [10,17-20]. Thus, the aim of the present study was
the selection and validation of new RGs for the differenti-
ation of normal and tumor lung specimens. Five putative
RGs (ESD, BTF3, HIST1H2BC, RPL30, YAP1) selected
from a meta-analysis of geneChip experiments [21] were
validated along with ACTB, GAPDH, RNA18S, PPIA,
PGK1, RPLP0 and POLR2A by qPCR assessment of their
expression levels on 18 paired normal lung and NSCLC
samples. Expression changes between and within these




Primary tumour samples and paired normal lung tissues
obtained from 18 NSCLC patients (11M, 7F) aged 41–79
(mean 62) during primary curative resection (not pre-
ceded by radiotherapy or chemotherapy) at the San Luigi
Hospital, Orbassano (Italy) between December 2003 and
March 2004 were immediately snap-frozen in liquid
nitrogen and stored at -80°C until RNA extraction. The
histological subtypes were: 7 adenocarcinomas (ADCA,
38.9%), 10 squamous cell carcinomas (SQCA, 55.6%)
and 1 broncoalveolar carcinoma (BAC, 5.5%). Prior writ-
ten and informed consent was obtained from each
patient. The study was approved by the appropriate ethi-
cal review board. The guidelines for good clinical practice
and the recommendations of the Declaration of Helsinki
for biomedical research involving human subjects were
followed.
RNA extraction and cDNA synthesis
Total RNA (totRNA) was isolated from lung specimens
with the RNeasy 96 Kit and Biorobot 8000 (Qiagen,
Hilden, Germany) according to the manufacturer's
instructions. RNA was extracted from 15–25 mg and 60–
80 mg of tumor and normal lung tissues specimens
respectively. To take account of the expression variability
due to cellular heterogeneity, totRNA was extracted from
a biological duplicate of both normal and tumour speci-
mens. Genomic DNA contaminations were removed by
on-column-DNAseI treatment. totRNA was then quanti-
fied with an Agilent 2100 Bioanalyzer (Agilent Technolo-
gies, Palo Alto, CA, USA) and stored at -80°C. Two µgr
totRNA were finally retro-transcribed with random hex-
amer primers and Multiscribe Reverse transcriptase
(MMLV) contained in the High Capacity cDNA Archive
Kit (Applied Biosystems, Foster City, CA), in accordance
with the manufacturer's suggestions.
Real-time PCR
Expression levels of the 5 putative and 7 commercial RGs
(ACTB, β-actin; GAPDH, glyceraldehyde-3-phosphate dehy-
drogenase; PGK1, phosphoglycerate kinase 1; POLR2A,
polymerase RNA II polypeptide A, 220kDa; PPIA, cyclophilin
A; rRNA 18S, 18S ribosomal RNA; RPLP0, ribosomal protein,
large, P0; ESD, esterase D/formylglutathione hydrolase; BTF3,
basic transcription factor 3; HIST1H2BC, histone 1 H2bc;
RPL30, ribosomal protein L30; YAP1, Yes-associated protein
1, 65kDa) and 3 target genes (BRCA1, breast cancer 1 early
onset; ERCC2, excision repair cross-complementing rodent
repair deficiency, complementation group 2; RRM2, ribonucle-
otide reductase M2 polypeptide) were evaluated with Taq-
Man Probes commercially available as "Assay on
Demand" (Applied Biosystems, Foster City, CA, USA)
with optimised primer and probe concentrations (Table
1). Quantitative PCR (qPCR) was performed on an ABIBMC Cancer 2006, 6:200 http://www.biomedcentral.com/1471-2407/6/200
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PRISM 7900HT Sequence Detection System (Applied Bio-
systems, Foster City, CA, USA) in 384 well plates assem-
bled by Biorobot 8000 (Qiagen, Hilden, Germany) and
the reaction was performed in a final volume of 20 µl. All
qPCR mixtures contained 1 µl of cDNA template (corre-
sponding approximately to 20 ng retro-transcribed
totRNA), 1× TaqMan Universal PCR Master Mix (2×)
(Applied Biosystems, Foster City, CA, USA) and 1× Assay-
on-Demand Gene Expression Assay Mix (20×). Cycle con-
ditions were as follows: after an initial 2-min hold at 50°C
to allow AmpErase-UNG activity, and 10 minutes at
95°C, the samples were cycled 40 times at 95°C for 15 sec
and 60°C for 1 minute. Baseline and threshold for Ct cal-
culation were set manually with the ABI Prism SDS 2.1
software. Automation allowed negligible intra-assay vari-
ation (≤5% CV) and low inter-assay variation (≤10% CV)
when evaluated on raw linear expression quantities.
Data analysis
Meta-analysis of expression data was performed by using
affy, MergeMaid and genefilter libraries implemented in
Bioconductor [22]. Statistical analyses were performed
with R [23]. Gene differential expression was considered
significant with an α = 0.05 and p-value <0.05. PCA (Prin-
cipal Component Analysis, [24]) and agglomerative hier-
archical clustering were performed with TMEV software
[25]. Assays on Demand's PCR efficiencies, evaluated by
cDNA dilution curves, ranged between 91% (rRNA18S,
RPL30) and 100% (POL2RA, ESD) with an average value
of 96%. Since PCR efficiencies were high and comparable
we used the theoretical value of 2 (100%) for gene expres-
sion quantification. So, fold changes in expression levels
between the normal and tumor paired samples were eval-
uated with 2-∆'Ct [7]. The expression of each target gene
was reported as 2-∆∆Ct[6].
The GeNorm Software [26] was obtained from the Gene
Quantification Home Page [27].
Biological replicates were treated as independent samples
in RGs raw Ct distribution analysis and geNorm analysis.
Their average Ct value was used in ∆'Ct calculation (i.e for
each sample mean Ct_tumor-mean Ct_normal) applied
to evaluate the RGs expression stability with equivalence
test. We also averaged the ∆Ct value (Ct target-Ct refer-
ence) of biological replicates to generate the mean ∆∆Ct
values used in PCA and agglomerative hierarchical cluster-




Five putative RGs were selected from a meta-analysis of a
subset of lung tissue transcription profilings [21]. To
secure a balanced set of tissues, the analysis focused on 17
normal samples, 18 ADCA (randomly selected from a
total of 127), 21 SQCA, 20 pulmonary carcinoids and 6
small-cell lung carcinomas. After RMA intensity calcula-
tion [28] and quantile normalization [29], an intensity fil-
ter was applied to remove all probe sets with intensity
≤100 in all experiments.
Tumour/normal gene expression similarity was measured
with the "integrative correlation" (IC) estimation, devel-
oped by Parmigiani et al. [30]. This reflects the general
consistency of gene expression among the different tissues
since it is generated using gene-to-gene correlation
obtained by all pairwise correlation for all genes across the
tissue groups. A variance/IC filter between each tumor
group versus the normal tissues was applied to select
probe sets with an inter-sample standard deviation (SD) ≤
Table 1: Gene expression assays.
Reference gene Gene symbol Gene name Assay on Demand
+ BTF3 * basic transcription factor 3 Hs00265768_m1
+ ESD * Esterase D/formylglutathione hydrolase Hs00382661_m1
+ HIST1H2BC * histone 1, H2bc Hs00830401_s1
+ RPL30 * ribosomal protein L30 Hs00265497_m1
+ YAP1 * Yes-associated protein 1, 65kDa Hs00371735_m1
+ POLR2A polymerase (RNA) II polypeptide A, 220kDa Hs_00172187_m1
+ PPIA cyclophilin A Hs_99999904_m1
+ PGK1 phosphoglycerate kinase 1 Hs_99999906_m1
+ rRNA18S 18S ribosomal RNA Hs99999901_s1
+ GAPDH glyceraldehyde-3-phosphate dehydrogenase Hs_99999905_m1
+ ACTB β-actin Hs_99999903_m1
+ RPLP0 ribosomal protein, large, P0 Hs99999902_m1
- BRCA1 breast cancer 1, early onset Hs00173237_m1
- ERCC2 excision repair cross-complementing rodent repair deficiency, complementation group 2 Hs00361161_m1
- RRM2 ribonucleotide reductase M2 polypeptide Hs00357247_g1
*indicates RGs selected from microarray data meta-analysis.BMC Cancer 2006, 6:200 http://www.biomedcentral.com/1471-2407/6/200
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0.5 and IC ≥ 0.2. All the 28 top ranked putative RGs dis-
played a nearly normal distribution of the residuals repre-
senting the expression differences between each tumor
sample versus normal samples (data not shown). Within
this set we selected five candidates RGs (ESD, BTF3,
HIST1H2BC, RPL30, YAP1) involved in different biologi-
cal processes and for which commercial gene expression
assays were available.
RGs expression ranges in lung tissues
The 12 RGs investigated displayed a wide range of Ct val-
ues (Figure 1) in separate evaluation of the paired sam-
ples. Except for rRNA18S (mean 9.8), the mean values fell
into two groups: group A (ESD and the other six commer-
cial RGs): 19–26; group B (the other four microarray-
selected RGs): over 26. The microarray-selected RGs (apart
from ESD) thus lay in a Ct range not usually covered by
commercial RGs and more close to that of our three target
genes (i.e. BRCA1, ERCC2, RRM2 with mean Ct values
were 31, 29 and 30 respectively). All genes showed a nor-
mal distribution pattern proved by Shapiro-Francia fitting
procedure (with α = 0.05) both in normal and tumor tis-
sue samples, evaluated with the Bioconductor Nortest
package.
RGs expression stability
To allow accurate quantification a RG should own a stable
expression among samples while to warrant a trustworthy
Expression levels of the 12 candidate RGs in normal and tumor lung tissue samples Figure 1
Expression levels of the 12 candidate RGs in normal and tumor lung tissue samples. Ct values for each RG are 
shown as medians (lines), 25th to 75th percentile (boxes) and range (whiskers). Hatched and open boxes represent tumor and 
normal samples respectively.BMC Cancer 2006, 6:200 http://www.biomedcentral.com/1471-2407/6/200
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quantification it should not be modulated by experimen-
tal conditions. Ideally to fulfill both conditions RG raw Ct
distribution of both normal and tumor populations
should thus be characterized by a narrow range of expres-
sion with comparable mean values. With reference to sta-
bility of expression in both normal and in tumor samples,
the lowest RNA transcription ranges (i.e Ct 75°quantile-
Ct 25°quantile) were associated withPOLR2A (normal =
0.73; tumor = 0.69) and rRNA18S (normal = 0.69; tumor
= 0.93), whereas the highest ranges were detected for
GAPDH (normal = 1.8; tumor = 2.2) and RPLP0 (normal
= 1.71; tumor = 1.84). Unfortunately, even when equal
amount of RNA input are used, retro-transcription reac-
tions are responsible for most of the variation in the
experimental determination of mRNA quantities [31,32].
We are thus unable to estimate how much the technical
(i.e. RT efficiency) and the biological (i.e. inter-samples)
variability contribute to the measured difference in RNA
quantities. Descriptive analysis of raw Ct distributions
provides only a rough estimate of RG stability that must
be confirmed by other approaches.
To investigate the experimental stability of RG transcrip-
tion we evaluated the significance of differences in RNA
transcription levels between the tumor and normal paired
samples, where the latter were used as calibrators in ∆'Ct
quantification approach [7,33]. Since in the two-sided t-
test the type II errors (false negatives) are uncontrollable,
we performed an equivalence test for dependent samples
[34] to investigate the null hypothesis of inequivalence
H0: µT-µN ≤ θL and µT-µN ≥ θU [35].
The equivalence test showed that only POLR2A, rRNA18S,
ESD and YAP1 had a differential expression, between the
paired samples, within the equivalence interval [θL = -1; θU
= 1], which represents a fold change variation interval
[0.5; 2]. All these four genes, unlike the others, were
indeed characterized by the lowest average fold change
(<1.8) and maximum fold change (<8). Conversely, the
greatest variability was associated with GAPDH, RPLP0
and HIST1H2BC (average fold change >6 and maximum
fold change ranging from 27 fold for HIST1H2BC to 80
fold for GAPDH) (Figure 2).
Fold change in expression levels Figure 2
Fold change in expression levels. Differences in gene expression levels between tumor and normal sample pairs were rep-
resented as average fold change variation (plot) and maximum fold change (bar). Filled columns refer to statistically stable 
expressed RGs.BMC Cancer 2006, 6:200 http://www.biomedcentral.com/1471-2407/6/200
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Gene expression stability was also investigated with
GeNorm software [26], which calculates the measure of
gene expression stability (M) of a putative RG based on
the average pairwise variation between all investigated
RGs. As requested by the software, Ct values were con-
verted to linear expression quantities by 2-∆Ct using the
highest expressed sample as calibrator. GeNorm con-
firmed our results by identifying rRNA18S and POLR2A as
the most stable genes (M = 0.436) preceded by ESD and
YAP1 (Figure 3a). Results were independent from the his-
tological classification of the lung tumors. The GeNorm
program also determines a normalization factor (NF)
needed to define the optimal number of RGs required for
an accurate normalization strategy. This is calculated from
two or more genes with the variable V as the pairwise var-
iation (Vn/Vn+1) between two sequential normalization
factors (NFn and NFn+1). The use of at least the three most
stable RGs (POL2RA, rRNA18S and ESD) is recommend
to improve the accuracy of normalized data, as suggested
by a V value below the cut-off of 0.15 (Figure 3b), which
was indicated by the authors as the limit beneath which it
would not be necessary to include additional reference
genes [36].
Significance of suitable RGs for normalization
Since normalization of the target genes versus a set of reli-
able RGs should result in the same fold change variation
with minimal fluctuations, Principal Component Analy-
sis [24] and agglomerative hierarchical clustering were
used to describe the homogeneity degree of target fold
change variation as a function of the reference used (Fig-
ure 4). Gene expression levels of three target genes
(RRM2, BRCA1, ERCC2) were normalized with respect to
each of the available RGs and expressed as -∆∆Ct using
normal paired samples as calibrator [6]. Both approaches
showed that the most homogeneous group of target fold
change evaluations was obtained when the most stable
RGs were used for normalization: POLR2A, rRNA18S,
YAP1 and ESD (Figure 4A–B filled dots). By contrast, the
commonly used RGs ACTB and GAPDH led to inconsist-
ent estimation of fold change (Figure 4A–B open trian-
gles).
Discussion
This paper describes the first systematic comparison of
several conventional and potential RGs and their effec-
tiveness as internal control for relative quantification in
lung cancer gene expression profiling. To increase data
reliability, we sought to control several variables by (1)
using matched pairs of normal and tumor lung samples
instead of unpaired samples to minimize inter-individual
variations that could arise from genotype profile; (2) ana-
lysing biological duplicates of each sample to take into
account the expression variability due to cellular heteroge-
neity in both normal and tumor lung tissues; (3) employ-
ing a liquid handling robot for most of the technical
procedures (i.e totRNA extraction and qPCR plates assem-
bling), to avoid operator variability; (4) by using high
quality certified qPCR reagents and (5) commercial RG
probes (Taqman Gene Expression Assay) properly
designed to guarantee maximum PCR efficiency and spe-
cificity [37] to allow trustworthy comparison in gene
expression stability evaluation. Furthermore, in view of
the unsuitability of conventional RGs, such as GAPDH or
ACTB, for most of the experimental situations [10,17-20],
we chose a microarray data meta-analysis to identify new
potential RGs. Since 2 out of 4 of the best performing RGs
(ESD and YAP1) identified in the present study belong to
the meta-analysis group, we can confirm the reliability of
this strategy in the identification of new candidate RGs
within a specific experimental condition. A further advan-
tage is the easier identification of candidate RGs expressed
at a comparable order of magnitude to target genes. This
might result in an improvement of data normalization
since, as highlighted by some researchers [38,39], at the
same Ct level, reference and target experience the same
condition and real-time RT-PCR kinetics with respect to
polymerase activation, reaction inactivation, stochastic
relation between target and primer concentration, and
reaction end product inhibition by the generated RT-PCR
product. However, the filtering procedures used to search
microarray data for stably expressed genes are biased for
low expressed genes.
RG expression stability within sample populations and
under experimental condition (tumor versus normal lung
specimens) has been evaluated by: (1) descriptive statistic;
(2) equivalence test; (3) GeNorm applet. All approaches
matched and show that for gene expression profiling in
NSCLC the most suitable reference genes to be used for
normalization are rRNA18S, POLR2A, ESD and YAP1. The
effectiveness of POLR2A, the main enzyme in mRNA tran-
scription, is further supported by others [40]. It is charac-
terized by stable expression among different tissues and it
is not modulated by treatment with TPA and ionomycin,
indicating resistance to cellular activation. The efficacy of
rRNA18S, however, has been criticized because: (1) it is
highly expressed, representing up to 80% of cellular RNA
and (2) it is transcribed by a specific RNA-polymerase
[41]. Nevertheless the results of the present study clearly
show that there are no significant differences between
rRNA18s and the other best performing RGs identified. In
addition, rRNA18s has already been recommended for
gene expression analysis in non-microdissected kidney
biopsies [10]. A recent assessment of RGs for lung cancer
studies by Liu et al. [42] has indicated that GAPDH is the
most suitable RG for qPCR studies in NSCLC tissue sam-
ples. In our study, however, all the statistical approaches
used suggested that GAPDH is far from being a valid RG
due to its evident modulation by the neoplastic transfor-BMC Cancer 2006, 6:200 http://www.biomedcentral.com/1471-2407/6/200
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GeNorm analysis of the 12 candidate RGs Figure 3
GeNorm analysis of the 12 candidate RGs. Selection of the RGs most suitable for normalization in lung cancer gene pro-
filing studies by GeNorm analysis. The results are presented according to the output file of the program. (a) stepwise exclusion 
of the least stable genes. The x-axis from left to right indicates the ranking of the genes according to their expression stability, 
while the Y-axis indicates the stability parameter M. (b) determination of the optimal number of RGs for normalization.BMC Cancer 2006, 6:200 http://www.biomedcentral.com/1471-2407/6/200
Page 8 of 10
(page number not for citation purposes)
mation. Our data are strongly in agreement with previous
indication that GAPDH is regulated in response to various
stimuli (i.e hypoxia, insulin, mitogen, EGF) and that its
transcript is elevated in various cancer tissues [43-45],
including lung cancer [46]. The discrepancy with Liu's
data could be related to the different ethnical origin of the
specimens. Even so, it probably reflects the employment
of a different data analysis approach. Liu et al., in fact,
defined GAPDH as the optimal RG because its expression
was almost equal to the mean expression of the other six
endogenous control genes they analyzed. This is not a sat-
isfactory parameter of RG stability because it is closely
dependent on the variability of the remaining RGs and
could not be used to assess their constancy within investi-
gated samples. Furthermore all their results refer to
pooled tumor and normal lung tissues samples and do
not consider whether and how high RG expression levels
were affected by malignant transformation. The latter
assessment is mandatory to warrant the validity of quan-
tification data [47].
Conclusion
Careful validation of RGs has been repeatedly advocated
as mandatory to ensure the accuracy of normalized data in
qPCR studies adopting relative quantification. Our results
invite the conclusion that for gene expression profiling in
NSCLC the RGs most suitable for normalization are
rRNA18S, POLR2A, ESD and YAP1. For accurate normali-
zation we recommend their concurrent use since this
results in more reliable quantification. Furthermore our
results pinpoint the limits of conventional RGs and sug-
gest that relatively simple meta-data analysis of genome
wide transcription profiling studies is a useful way of
identifying putative RGs.
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